AKRO Akero Therapeutics, Inc.

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

$10.37  -0.36 (-3.31%)
As of 06/24/2022 15:59:58 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/20/2019
Outstanding shares:  35,022,935
Average volume:  530,125
Market cap:   $375,445,863
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BK7Y2V9

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   2.48
PS ratio:   0.00
Return on equity:   -76.24%
Net income %:   0.00%